TCBP Provides Shareholder Update And Highlights Upcoming Milestones; Highlights ~$11.6M Cost-Savings
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm (Holdings) PLC (NASDAQ:TCBP), a clinical stage biotechnology company, announced significant operational achievements including FDA clearance for a Phase 1B study in AML, a new collaboration with Queen Mary University of London, and cost-savings of approximately $11.6M. The company successfully dosed the final patient in the ACHIEVE Study safety cohort and looks forward to interim data in 2024. TCBP also highlighted its focus on strategic partnerships and platform expansion into anti-fungal and anti-bacterial programs.
February 14, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TC BioPharm announced FDA clearance for a Phase 1B AML study, a new collaboration, and significant cost-savings, indicating strong operational progress and strategic focus.
The FDA clearance for the Phase 1B study in AML, the collaboration with Queen Mary University of London, and the significant cost-savings are all positive developments that indicate TCBP is making significant operational progress. These achievements are likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100